Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR | P43088 | 5/20 | 0.40 |
| ▸ | RORB | Q92753 | 2/20 | 0.39 |
| ▸ | CTSA | P10619 | 4/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 4/20 | 0.37 |
| ▸ | PLK1 | P53350 | 1/20 | 0.37 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2372623 | 0.93 | TRPV4 (0.38) | PTGFRRORBCTSATRPV4PLK1 | |
| SCHEMBL2372484 | 0.90 | CTSA (0.38) | PTGFRRORBCTSATRPV4PDE4B | |
| SCHEMBL2373839 | 0.90 | PTGFR (0.46) | PTGFRRORBCTSA | |
| SCHEMBL2372098 | 0.87 | TRPV4 (0.40) | PTGFRTRPV4PLK1 | |
| SCHEMBL2372142 | 0.86 | CTSA (0.44) | PTGFRRORBCTSATRPV4PLK1 | |
| SCHEMBL2373257 | 0.85 | TRPV4 (0.39) | PTGFRCTSATRPV4 | |
| SCHEMBL2465453 | 0.84 | TRPV4 (0.38) | PTGFRTRPV4 | |
| SCHEMBL2373699 | 0.84 | CTSA (0.44) | PTGFRRORBCTSATRPV4 | |
| SCHEMBL2372631 | 0.84 | TRPV4 (0.39) | PTGFRRORBCTSATRPV4 | |
| SCHEMBL2463806 | 0.83 | DHODH (0.54) | PTGFRRORBCTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2549872-B1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2015-11-25 | — | — | EP | disclosed |
| US-8658636-B2 | TRPV4 antagonists | GlaxoSmithKline, LLC (US) | 2014-02-25 | — | — | US | disclosed |
| EP-2549872-A1 | TRPV4 ANTAGONISTS | GlaxoSmithKline LLC (US) | 2013-01-30 | — | — | EP | disclosed |
| US-20130012499-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2013-01-10 | — | — | US | disclosed |
| WO-2011119701-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012499-A1 | TRPV4 ANTAGONISTS | TRPV4, TRPV2, TRPV5 | PTGFR 703/4885RORB 1566/4885CTSA 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.